Patrick Nylund
YOU?
Author Swipe
View article: Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma
Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma Open
Introduction Mantle cell lymphoma (MCL) is characterized by biological and clinical heterogeneity ranging from an indolent to highly aggressive lymphoma. Although prognosis is improving, prolonged impairment of quality-of-life due to treat…
View article: Synaptic transmission promotes brain metastatic outgrowth in breast cancer
Synaptic transmission promotes brain metastatic outgrowth in breast cancer Open
This work demonstrates that normal neuron-to-neuron signaling machinery is hijacked by metastasizing cancer cells during their outgrowth in the central nervous system.
View article: Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma
Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma Open
Multiple myeloma (MM) is a hematological disease of the plasma cell that remains clinically challenging despite the development of novel therapies. Epigenetic alterations have been demonstrated to contribute to MM pathogenesis, yet compreh…
View article: Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma
Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma Open
Introduction Mantle cell lymphoma (MCL), a rare and incurable B-cell malignancy, is characterized by extensive biological and clinical heterogeneity with disease courses ranging from indolent to highly aggressive. Patients who progress wit…
View article: Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression
Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression Open
Introduction: Despite the availability of effective treatments, the majority of mantle cell lymphoma (MCL) patients eventually relapse. Large-scale plasma proteomics analysis has shown promise for identifying novel prognostic biomarkers, a…
View article: Evaluation of coverage, generalisability and validity of the <scp>U‐CAN</scp> lymphoma biobank in Sweden: A comparison with nationwide registers
Evaluation of coverage, generalisability and validity of the <span>U‐CAN</span> lymphoma biobank in Sweden: A comparison with nationwide registers Open
Summary Validation of biobanks and large cancer cohorts is essential in ensuring high‐quality research results. We examined the coverage, generalisability and validity of the lymphoma collection of the Uppsala‐Umeå Comprehensive Cancer Con…
View article: Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma Open
In Mantle Cell Lymphoma (MCL), the role of macrophages within the tumour microenvironment (TME) has recently gained attention due to their impact on prognosis and response to therapy. Despite their low absolute number in MCL tumour tissue,…
View article: The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma
The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma Open
Extensive genome-wide sequencing efforts have unveiled the intricate regulatory potential of long non-protein coding RNAs (lncRNAs) within the domain of haematological malignancies. Notably, lncRNAs have been found to directly modulate chr…
View article: <i>PVT1</i> interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
<i>PVT1</i> interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma Open
Multiple myeloma is a heterogeneous hematological disease that originates from the bone marrow and is characterized by the monoclonal expansion of malignant plasma cells. Despite novel therapies, multiple myeloma remains clinically challen…
View article: One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies Open
Aberrant DNA methylation, dysregulation of chromatin-modifying enzymes, and microRNAs (miRNAs) play a crucial role in haematological malignancies. These epimutations, with an impact on chromatin accessibility and transcriptional output, ar…